Form 4: Verona Pharma Director Acquires Share Options
SEC Form 4
Christina Ackermann, a director of Verona Pharma plc, acquired share options exercisable for 240,000 ordinary shares on April 29, 2024.
Summary
- Christina Ackermann, a director at Verona Pharma plc, filed a Form 4 on April 30, 2024.
- The form reports a transaction that occurred on April 29, 2024, where Ackermann acquired share options.
- These options are exercisable for 240,000 ordinary shares of Verona Pharma plc.
- The exercise price of the options is $1.9338 per share.
- The options vest in four equal installments on July 29, 2024, October 29, 2024, January 29, 2025, and April 29, 2025.
- The options expire on April 28, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock options, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity incentives provided to company directors.
Stakeholder Impact
- The granting of share options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 04/29/2024 | Date of transaction: Director acquired share options. |
| 07/29/2024 | First vesting date for 25% of the options. |
| 10/29/2024 | Second vesting date for 25% of the options. |
| 01/29/2025 | Third vesting date for 25% of the options. |
| 04/29/2025 | Fourth vesting date for 25% of the options. |
| 04/28/2034 | Expiration date of the options. |
| 04/30/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.